Cargando…

Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer

PURPOSE: This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). METHODS: Serial plasma samples were collected from 30 patients with EGFR-driven non-sma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moiseyenko, Fedor V., Kuligina, Ekaterina S., Zhabina, Albina S., Belukhin, Sergey A., Laidus, Tatiana A., Martianov, Aleksandr S., Zagorodnev, Kirill A., Sokolova, Tatyana N., Chuinyshena, Svetlana A., Kholmatov, Maxim M., Artemieva, Elizaveta V., Stepanova, Ekaterina O., Shuginova, Tatiana N., Volkov, Nikita M., Yanus, Grigoriy A., Imyanitov, Evgeny N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853017/ https://www.ncbi.nlm.nih.gov/pubmed/35171360 http://dx.doi.org/10.1007/s10147-022-02128-6

Ejemplares similares

Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma
por: Kuligina, Ekaterina, et al.
Publicado: (2021)

Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1
por: Mitiushkina, Natalia V., et al.
Publicado: (2022)

Hereditary cancer syndromes
por: Imyanitov, Evgeny N, et al.
Publicado: (2023)

Comprehensive evaluation of the test for 5′‐/3′‐end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer
por: Mitiushkina, Natalia V., et al.
Publicado: (2022)

Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine
por: Sokolova, Tatiana N., et al.
Publicado: (2021)

Targeted Delivery of (111)In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody
por: Karyagina, Tatiana S., et al.
Publicado: (2020)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

Molecular testing for colorectal cancer: Clinical applications
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

Integration of the blood test into the low-dose computed tomography lung cancer screening: reliable discrimination between malignant and non-malignant radiographic findings
por: Kuligina, Ekaterina S., et al.
Publicado: (2021)

Molecular Analysis of Biliary Tract Cancers with the Custom 3′ RACE-Based NGS Panel
por: Mitiushkina, Natalia V., et al.
Publicado: (2023)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
por: Gorodnova, Tatiana V., et al.
Publicado: (2021)

Drug therapy for hereditary cancers
por: Imyanitov, Evgeny N, et al.
Publicado: (2011)

Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab
por: Orlov, Sergey V., et al.
Publicado: (2020)

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
por: Sokolenko, Anna P., et al.
Publicado: (2023)

Hereditary Breast-Ovarian Cancer Syndrome in Russia
por: Sokolenko, A.P., et al.
Publicado: (2010)

EGFR Suppression Inhibits the Sphere Formation of MCF7 Cells Overexpressing EGFR
por: Novak, D. D., et al.
Publicado: (2023)

Antitumor Activity of Auger Electron Emitter (111)In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression
por: Rosenkranz, Andrey A., et al.
Publicado: (2018)

Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical Findings
por: Kushnareva, Ekaterina, et al.
Publicado: (2022)

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
por: Orlov, Sergey V., et al.
Publicado: (2021)

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
por: Orlova, Kristina V., et al.
Publicado: (2019)

Two-Dimensional Plasmons in Laterally Confined 2D Electron Systems
por: Zagorodnev, Igor V., et al.
Publicado: (2023)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion
por: Moiseyenko, Vladimir M, et al.
Publicado: (2018)

Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation
por: Jones, Sylwia, et al.
Publicado: (2020)

egfr overexpression in squamous cell carcinoma of the penis
por: Lavens, N., et al.
Publicado: (2010)

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
por: Martianov, Aleksandr S., et al.
Publicado: (2023)

Modulation of EGFR Activity by Molecularly Imprinted Polymer Nanoparticles Targeting Intracellular Epitopes
por: Piletsky, Stanislav S., et al.
Publicado: (2023)

Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling
por: Sugiyama, Michael G., et al.
Publicado: (2023)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas
por: Tiurin, Vladislav I., et al.
Publicado: (2023)

VEGF-A, VEGF-C, VEGF-R2, EGFR and HER2 in serum plus EGFR in tissue of patients with triple-negative breast cancer
por: Iosifidou, R, et al.
Publicado: (2009)

The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors
por: Chang, Xiaofei, et al.
Publicado: (2013)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
por: Sung, Mike R., et al.
Publicado: (2021)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

ALK, ROS1, RET and NTRK1–3 Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers
por: Mulkidjan, Rimma S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f2gku7m3vgvskucsirt7gflqs4